This article is more than 5 years old. Information may no longer be current.
Top five news stories posted in July
Click Here to Manage Email Alerts
Endocrine Today has compiled a list of the top five news reports posted in July.
Healio.com/Endocrinology readers were interested in technology for measuring cortisol levels and for managing glucose in the hospital, cardiovascular disease management in diabetes, and more.
Wearable patch measures cortisol in sweat
Researchers from Stanford University have designed a wearable device that measures how much cortisol a person is producing through sweat.
Most adults with diabetes, CVD do not meet secondary prevention targets
Less than one-third of adults with diabetes and cardiovascular disease achieve goals for secondary prevention, including smoking cessation, use of prophylactic medications, and blood pressure and lipid control.
FDA clears first glucose meter for critically ill patients
The FDA has granted 510(k) clearance for the first finger-stick capillary testing meter for critically ill patients with diabetes, Nova Biomedical announced in a press release.
Cardiologists should consider prescribing GLP1 agents for CVD prevention in type 2 diabetes
Although endocrinologists may routinely prescribe the newer classes of diabetes drugs approved for cardiovascular risk reduction, cardiologists and primary care providers should also consider using these agents for patients with type 2 diabetes and heart disease.
CARMELINA results demonstrate CV neutral effect with linagliptin in diabetes
Researchers with the CARMELINA cardiovascular outcomes trial announced positive top-line results for the DPP-IV inhibitor linagliptin, noting the drug demonstrated similar CV safety vs. placebo in adults with type 2 diabetes and high CV risk.